Chikungunya vaccine: Valneva reports excellent final Phase 1 results
by Press Release from Outbreak News Today on (#4V9QR)
Valneva SE, a biotech company developing and commercializing vaccines for infectious diseases with major unmet medical needs, today announced excellent final Phase 1 results for its single-shot chikungunya vaccine candidate, VLA1553. The objectives of the Phase 1 study (VLA1553-101) were to assess the safety and immunogenicity profile of VLA1553 after a single vaccination across three ["]
The post Chikungunya vaccine: Valneva reports excellent final Phase 1 results appeared first on Outbreak News Today.